(Reuters) – Pharmaceutical companies selling drugs in parts of the San Francisco Bay area would be required to submit plans for incinerating or safely disposing of unused medication under a plan advanced by county officials this week.The measure, billed by supporters as the first of its kind in the

ปัญหาโควิด-19 (COVID-19) ในประเทศรายได้น้อยถึงปานกลางถือเป็นความท้าทายสำคัญของระบบสุขภาพ C19economics.org คือแพลตฟอร์มออนไลน์ที่จะเป็นส่วนหนึ่งในการช่วยให้ผ่านพ้นความท้าทายสำคัญนี้ไปได้ แล้ว C19economics.org คืออะไร? HITAP ขอเชิญทุกท่านโดยเฉพาะนักวิจัยและผู้กำหนดนโยบายสุขภาพมารู

A painkiller as powerful as morphine, but without most of the side-effects, has been found in the deadly venom of the black mamba, say French scientists.The predator, which uses neurotoxins to paralyse and kill small animals, is one of the fastest and most dangerous snakes in Africa.However, tests o

 It is an uncomfortable question that, in today’s world, is often asked by expectant mothers who had more than one male partner at the time they became pregnant. Who is the father?With more than half of births to women under 30 now out of wedlock, it is a question that may arise more often.Now blood

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T

Background As universal health coverage schemes mature, governments often seek to improve patient choice, whilst ensuring that services are appropriate, high-quality, and financially sustainable, especially for high-cost interventions like dialysis. Policy levers to manage supply and demand for ser

(Reuters) – AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain’s second biggest drugmaker said on Tuesday.Peripheral artery disease affects around 27 million people in Europe and North America, with s

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

(Reuters) – Republican governors bent on rejecting the healthcare law’s expanded insurance coverage for millions of low-income Americans may see their gambit backfire if their party fails to sweep the November elections.Five governors have vowed to opt out of the Medicaid expansion for low-income pe